In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Baroreflex activation therapy - another piece of the puzzle for heart failure with reduced ejection fraction.

Session Baroreflex activation therapy for resistant hypertension and heart failure: the new piece in the puzzle

Speaker Johann Bauersachs

Congress : ESC Congress 2018

  • Topic : hypertension
  • Sub-topic : Hypertension: Device Treatment and Intervention
  • Session type : Satellite Symposium
  • FP Number : 5810
  • Organised by Charité supported with an educational grant from CVRx
The ESC does not have the copyright for the slides and video of this presentation

Other presentations from this session

Baroreflex activation therapy for resistant hypertension and heart failure: the new piece in the puzzle

  • ESC Congress 2018
  • Hypertension
  • Satellite Symposium
  • 28 August 2018
  • 13:00 - 14:00
session 2018 2018
5

Other presentations from this speaker

no speaker photo speaker

Johann Bauersachs

Hannover Medical School, Hannover (Germany)

25


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are